Show simple item record

dc.contributor.authorLeahy, B
dc.contributor.authorHoneybourne, D
dc.contributor.authorBrear, S G
dc.contributor.authorCarroll, K B
dc.contributor.authorThatcher, Nick
dc.contributor.authorStretton, T B
dc.date.accessioned2010-07-21T10:34:59Z
dc.date.available2010-07-21T10:34:59Z
dc.date.issued1985-01
dc.identifier.citationTreatment of malignant pleural effusions with intrapleural Corynebacterium parvum or tetracycline. 1985, 66 (1):50-4 Eur J Respir Disen
dc.identifier.issn0106-4339
dc.identifier.pmid3979476
dc.identifier.urihttp://hdl.handle.net/10541/108011
dc.description.abstractThirty two patients with malignant pleural effusion were randomly allocated to treatment with intrapleural Corynebacterium parvum or tetracycline hydrochloride in an attempt to prevent symptomatic recurrence of pleural fluid. Success in preventing recurrence of fluid at one month, using up to 2 doses of each drug, was 14 of 16 cases for Corynebacterium parvum, 5 of 9 for tetracycline given via an intercostal needle, and 6 of 7 for tetracycline given through an intercostal tube. These difference were not statistically significant. Corynebacterium parvum was significantly more likely to produce pyrexia equal or greater than 38 degrees C (P less than 0.001) and pain requiring analgesia (P less than 0.05) than tetracycline hydrochloride. Corynebacterium parvum is a useful agent for the management of malignant pleural effusion, but is associated with more side effects than tetracycline.
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshBacterial Vaccines
dc.subject.meshDrug Evaluation
dc.subject.meshFemale
dc.subject.meshFever
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasms
dc.subject.meshPain
dc.subject.meshPleural Effusion
dc.subject.meshPropionibacterium acnes
dc.subject.meshRandom Allocation
dc.subject.meshTetracyclines
dc.titleTreatment of malignant pleural effusions with intrapleural Corynebacterium parvum or tetracycline.en
dc.typeArticleen
dc.identifier.journalEuropean Journal of Respiratory Diseasesen
html.description.abstractThirty two patients with malignant pleural effusion were randomly allocated to treatment with intrapleural Corynebacterium parvum or tetracycline hydrochloride in an attempt to prevent symptomatic recurrence of pleural fluid. Success in preventing recurrence of fluid at one month, using up to 2 doses of each drug, was 14 of 16 cases for Corynebacterium parvum, 5 of 9 for tetracycline given via an intercostal needle, and 6 of 7 for tetracycline given through an intercostal tube. These difference were not statistically significant. Corynebacterium parvum was significantly more likely to produce pyrexia equal or greater than 38 degrees C (P less than 0.001) and pain requiring analgesia (P less than 0.05) than tetracycline hydrochloride. Corynebacterium parvum is a useful agent for the management of malignant pleural effusion, but is associated with more side effects than tetracycline.


This item appears in the following Collection(s)

Show simple item record